* IGM Biosciences Inc IGMS.OQ IGMS.O is expected to show
a
rise in quarterly revenue when it reports results on May 8
(estimated).
* The Mountain View California-based company is expected to
report revenue of $1.644 million, according to the mean estimate
from 9 analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for IGM Biosciences Inc
is
for a loss of $1.37 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for IGM
Biosciences
Inc is $33, above its last closing price of $12.58.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -1.25 -1.19 Beat 4.5
Sep. 30 2022 -1.44 -1.43 -1.32 Beat 7.5
Jun. 30 2022 -1.27 -0.94 -1.33 Missed -41.5
Mar. 31 2022 -1.61 -1.61 -1.53 Beat 5.2
Dec. -1.37 -1.54 -1.50 Beat 2.7
31 2021
Sep. 30 2021 -1.37 -1.37 -1.32 Beat 3.4
Jun. 30 2021 -1.19 -1.17 -1.16 Beat 0.6
Mar. 31 2021 -0.96 -0.98 -0.95 Beat 3.1
This summary was machine generated May 5 at 11:41 GMT. All
figures in US dollars unless otherwise stated